Cognito chief executive Brent Vaughan expects the new study to wrap up in 2025. Potentially, he said, the company could submit its device to the FDA and gain approval by the end of that year.

Cognito Therapeutics is a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease.

(Cognito Therapeutics) The Hope study will task upwards of 400 people with mild to moderate Alzheimer’s with using the noninvasive device at home every day for 12 months, throughout which they ...

Cogito ergo sum. I think, therefore I am. Bona fide. Good faith. Save. Log in, register or subscribe to save articles for later. License this article. Education; Most Viewed in National. Loading ...

BOSTON--(BUSINESS WIRE)--Cogito, the leader in real-time coaching and guidance for the enterprise, announced a new and enhanced solution targeted at improving the employee experience for frontline ...

Cognito Therapeutics Inc. became the latest company to secure a large-scale trial to treat Alzheimer’s disease. Unlike most other remedies in development today, this one involves a device rather ...

Cognito’s analysis compared participants treated in the Overture study, which enrolled 76 people, to historical data collected from a separate, decade-long, global study conducted by the ...

Cognito’s headset uses light and sound therapy to stimulate gamma waves. Cognito Therapeutics The device, which looks like a blend of sunglasses and headphones, emits pulsing lights and sounds.

J ust as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment ...

Integrated communications specialist Cognito has bolstered its Singapore and Hong Kong offices with two new senior promotions, of which Emma Arora (pictured left) is promoted to managing director ...